Amundi Pioneer Asset Management Inc. lessened its holdings in SAGE Therapeutics Inc (NASDAQ:SAGE) by 14.1% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 103,937 shares of the biopharmaceutical company’s stock after selling 17,071 shares during the period. Amundi Pioneer Asset Management Inc. owned approximately 0.22% of SAGE Therapeutics worth $16,741,000 as of its most recent SEC filing.
Other hedge funds have also modified their holdings of the company. Two Sigma Advisers LP purchased a new position in SAGE Therapeutics in the 4th quarter valued at approximately $2,125,000. Xact Kapitalforvaltning AB purchased a new position in SAGE Therapeutics in the 4th quarter valued at approximately $600,000. California State Teachers Retirement System boosted its position in SAGE Therapeutics by 7.8% in the 4th quarter. California State Teachers Retirement System now owns 59,635 shares of the biopharmaceutical company’s stock valued at $9,822,000 after buying an additional 4,306 shares during the period. HBK Investments L P purchased a new position in SAGE Therapeutics in the 4th quarter valued at approximately $2,800,000. Finally, Cornerstone Capital Management Holdings LLC. raised its holdings in shares of SAGE Therapeutics by 3.4% in the 4th quarter. Cornerstone Capital Management Holdings LLC. now owns 15,038 shares of the biopharmaceutical company’s stock valued at $2,476,000 after purchasing an additional 500 shares in the last quarter.
In related news, CFO Kimi Iguchi sold 28,153 shares of SAGE Therapeutics stock in a transaction on Wednesday, April 25th. The shares were sold at an average price of $142.73, for a total transaction of $4,018,277.69. Following the sale, the chief financial officer now directly owns 63,499 shares in the company, valued at approximately $9,063,212.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director James M. Frates sold 7,000 shares of SAGE Therapeutics stock in a transaction on Tuesday, May 8th. The stock was sold at an average price of $154.00, for a total transaction of $1,078,000.00. Following the sale, the director now owns 12,000 shares in the company, valued at $1,848,000. The disclosure for this sale can be found here. Insiders have sold a total of 106,288 shares of company stock worth $16,811,692 over the last quarter. 5.10% of the stock is owned by company insiders.
Shares of NASDAQ:SAGE opened at $153.46 on Friday. SAGE Therapeutics Inc has a 12 month low of $59.57 and a 12 month high of $195.97. The firm has a market cap of $7.50 billion, a P/E ratio of -21.64 and a beta of 3.04.
SAGE Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($1.68) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.84) by $0.16. During the same quarter last year, the business earned ($1.52) EPS. analysts predict that SAGE Therapeutics Inc will post -8.52 earnings per share for the current fiscal year.
SAGE has been the topic of a number of analyst reports. Cowen restated a “buy” rating and issued a $202.00 price objective on shares of SAGE Therapeutics in a report on Tuesday, March 20th. LADENBURG THALM/SH SH initiated coverage on shares of SAGE Therapeutics in a report on Wednesday, June 6th. They issued a “buy” rating and a $230.00 price objective on the stock. ValuEngine upgraded shares of SAGE Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Morgan Stanley initiated coverage on shares of SAGE Therapeutics in a report on Monday, February 26th. They issued an “overweight” rating and a $225.00 price objective on the stock. Finally, SunTrust Banks raised their price objective on shares of SAGE Therapeutics to $203.00 and gave the company a “buy” rating in a report on Wednesday, February 28th. Two research analysts have rated the stock with a sell rating, one has given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $188.94.
SAGE Therapeutics Company Profile
Sage Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system disorders. Its lead product candidate comprises brexanolone, a proprietary intravenous formulation of allopregnanolone that has completed III clinical trials for the treatment of post-partum depression (PPD).
Want to see what other hedge funds are holding SAGE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SAGE Therapeutics Inc (NASDAQ:SAGE).
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.